H.C. Wainwright Keeps Their Buy Rating on Bright Minds Biosciences (DRUG)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Bright Minds Biosciences (DRUG) with a $145 price target. Trucchio, a 5-star analyst in the Healthcare sector, maintains this view alongside an overall Strong Buy consensus for the stock, which has an average price target of $164.26.
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, with a price target of $145.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Trucchio is a 5-star analyst with an average return of 30.6% and a 55.08% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Aligos Therapeutics, and Silence Therapeutics.
Currently, the analyst consensus on Bright Minds Biosciences is a Strong Buy with an average price target of $164.26.